Epigenetic Memory in Glioblastoma: The PKC–DNMT1–MGMT Axis as a Mechanism of Resistance and Evolution

Aiyana Jade Adams Background: Glioblastoma (GBM) is the most lethal and recurrent primary brain tumor in adults, classified as a WHO Grade IV astrocytoma.¹⁻³ Despite aggressive multimodal treatment, median survival remains only 12–15 months, largely due to adaptive resistance mechanisms.¹⁻³ One of the most well-established predictors of TMZ response is…
Cancer Featured Abstracts

Using Anti-Angiogenic Therapy to Improve the Efficacy of PD/PD-L1 Immunotherapies for Lung Cancer

Natalie Gonzalez Introduction The leading cause of cancer deaths is attributed to lung cancer, with 80% of all cases associated with non–small cell lung cancer (NSCLC).1,2 One therapy currently being used is anti-PD-1/PD-L1 monotherapy.1 However, the tumor microenvironment (TME) of hypoxia and hyperangiogenesis, caused by overexpression of vascular endothelial growth…
Cancer Immunology

At the crossroads: Car-T cell therapies shifting gears in AML treatment

Sanjna Sandeep Background: Acute Myeloid Leukemia (AML) is a cancer of the stem cell precursors for hematopoietic cells, causing over 80,000 deaths yearly with a 30.5% 5-year survival rate in the US1. Highly varied gene alterations drive AML’s progression, leading to life-threatening cytopenias1. The “3+7” chemotherapy regimen is the standard…
Cancer Engineering Medicine Featured Abstracts Immunology